Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:42:02.115Z.
Calculation as of: 2026-10-06T18:42:02.115Z.
Quote observation: 2026-10-06T18:39:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$111.89M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.02M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.98M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.06M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.18M
EV/EBITDA Ratio
N/A
TTM Avg
20.46x
3Y Avg
22.62x
5Y Avg
53.44x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $111.89M | N/A | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.02M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.98M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.18M | N/A | 20.46x | 22.62x | 53.44x |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.30M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
